AI-driven drug discovery, as J&J is leveraging generative AI to accelerate clinical trials and identify small-molecule candidates, providing a significant growth tailwind for the healthcare sector.

An aging global population in key markets like the U.S., Europe, and China, which continues to drive increased demand for J&J’s pharmaceutical products and medical devices, such as hip/knee replacements and cardiovascular pumps.

Impact of drug pricing legislation, such as the Inflation Reduction Act (IRA) in the U.S., which began affecting the pricing of major drugs like Stelara and Xarelto in January 2026, potentially limiting long-term profitability through 'Maximum Fair Price' mandates.